Last 12 months
Inside the activity.
0 purchase rows · 75 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 11 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 6 |
| Feb 2026 | 0 | 8 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 4 |
| May 2026 | 0 | 5 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 15 |
| Sep 2026 | 0 | 7 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 06, 2020 Filed Apr 7, 2020 21:34 UTC |
Cogan John FrancisDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-013405 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,655 Underlying: Common Stock · 2,413 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 21:34 UTC |
Cogan John FrancisDirector
|
SaleCommon Stock | 2,413 | $79.52 | $191,881.76 |
DisclosureSEC source: 0001127602-20-013405 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 21:34 UTC |
Cogan John FrancisDirector
|
Exercise / conversionCommon Stock | 2,413 | $19.63 | $47,367.19 |
DisclosureSEC source: 0001127602-20-013405 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 30, 2020 Filed Mar 31, 2020 19:00 UTC |
Cogan John FrancisDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-012212 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,068 Underlying: Common Stock · 2,413 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| March 30, 2020 Filed Mar 31, 2020 19:00 UTC |
Cogan John FrancisDirector
|
SaleCommon Stock | 2,413 | $75.35 | $181,819.55 |
DisclosureSEC source: 0001127602-20-012212 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| March 30, 2020 Filed Mar 31, 2020 19:00 UTC |
Cogan John FrancisDirector
|
Exercise / conversionCommon Stock | 2,413 | $19.63 | $47,367.19 |
DisclosureSEC source: 0001127602-20-012212 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:16 UTC |
Lofton Kevin EDirector
|
GrantPhantom Stock · Derivative | 24.5203 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-012368 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,762.4998 Underlying: Common Stock · 24.5203 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:20 UTC |
Whitley Richard JamesDirector
|
GrantPhantom Stock · Derivative | 62.4252 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-012372 · form4.xml · derivative · entry 1 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,032.9378 Underlying: Common Stock · 62.4252 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 00:42 UTC |
Cogan John FrancisDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-011900 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,481 Underlying: Common Stock · 2,413 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 00:42 UTC |
Cogan John FrancisDirector
|
SaleCommon Stock | 2,413 | $75.27 | $181,626.51 |
DisclosureSEC source: 0001127602-20-011900 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 00:42 UTC |
Cogan John FrancisDirector
|
Exercise / conversionCommon Stock | 2,413 | $19.63 | $47,367.19 |
DisclosureSEC source: 0001127602-20-011900 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 00:01 UTC |
Cogan John FrancisDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-011172 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,894 Underlying: Common Stock · 2,413 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 00:01 UTC |
Cogan John FrancisDirector
|
SaleCommon Stock | 2,413 | $67.26 | $162,298.38 |
DisclosureSEC source: 0001127602-20-011172 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 00:01 UTC |
Cogan John FrancisDirector
|
Exercise / conversionCommon Stock | 2,413 | $19.63 | $47,367.19 |
DisclosureSEC source: 0001127602-20-011172 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:10 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
GrantRestricted Stock Unit · Derivative | 5,180 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-010508 · form4.xml · derivative · entry 6 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,746 Underlying: Common Stock · 5,180 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:10 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 17,630 | $0.00 Strike: $72.34 | $0.00 |
DisclosureSEC source: 0001127602-20-010508 · form4.xml · derivative · entry 5 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,630 Underlying: Common Stock · 17,630 shares Expires 2030-03-10 F5 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:10 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,865 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-010508 · form4.xml · derivative · entry 4 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,566 Underlying: Common Stock · 1,865 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:10 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Tax withholdingCommon Stock | 524 | $72.34 | $37,906.16 |
DisclosureSEC source: 0001127602-20-010508 · form4.xml · nonDerivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,199 Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:10 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionCommon Stock | 1,865 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-010508 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:14 UTC |
Parsey MerdadChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 13,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-010510 · form4.xml · derivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,120 Underlying: Common Stock · 13,820 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four- year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four- year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:14 UTC |
Parsey MerdadChief Medical Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 82,120 | $0.00 Strike: $72.34 | $0.00 |
DisclosureSEC source: 0001127602-20-010510 · form4.xml · derivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,120 Underlying: Common Stock · 82,120 shares Expires 2030-03-10 F1 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:15 UTC |
Dickinson Andrew DEVP, Chief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 12,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-010511 · form4.xml · derivative · entry 6 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,116 Underlying: Common Stock · 12,100 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:15 UTC |
Dickinson Andrew DEVP, Chief Financial Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 71,850 | $0.00 Strike: $72.34 | $0.00 |
DisclosureSEC source: 0001127602-20-010511 · form4.xml · derivative · entry 5 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,850 Underlying: Common Stock · 71,850 shares Expires 2030-03-10 F5 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:15 UTC |
Dickinson Andrew DEVP, Chief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 769 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-010511 · form4.xml · derivative · entry 4 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,016 Underlying: Common Stock · 769 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:15 UTC |
Dickinson Andrew DEVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 356 | $72.34 | $25,753.04 |
DisclosureSEC source: 0001127602-20-010511 · form4.xml · nonDerivative · entry 3 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,400 Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:15 UTC |
Dickinson Andrew DEVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 769 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-010511 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:18 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
GrantRestricted Stock Unit · Derivative | 43,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-010513 · form4.xml · derivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,132 Underlying: Common Stock · 43,200 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:18 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 256,620 | $0.00 Strike: $72.34 | $0.00 |
DisclosureSEC source: 0001127602-20-010513 · form4.xml · derivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,620 Underlying: Common Stock · 256,620 shares Expires 2030-03-10 F1 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:30 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
GrantRestricted Stock Unit · Derivative | 10,370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-010517 · form4.xml · derivative · entry 5 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,552 Underlying: Common Stock · 10,370 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:30 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 61,590 | $0.00 Strike: $72.34 | $0.00 |
DisclosureSEC source: 0001127602-20-010517 · form4.xml · derivative · entry 4 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,590 Underlying: Common Stock · 61,590 shares Expires 2030-03-10 F2 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:30 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,950 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001127602-20-010517 · form4.xml · derivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650 Underlying: Common Stock · 2,950 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:30 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
SaleCommon Stock | 2,950 | $75.55 | $222,872.50 |
DisclosureSEC source: 0001127602-20-010517 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,644 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:30 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Exercise / conversionCommon Stock | 2,950 | $24.30 | $71,670.25 |
DisclosureSEC source: 0001127602-20-010517 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:25 UTC |
Mercier JohannaChief Commercial Officer
|
GrantRestricted Stock Unit · Derivative | 12,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-010515 · form4.xml · derivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,120 Underlying: Common Stock · 12,100 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four- year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four- year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:25 UTC |
Mercier JohannaChief Commercial Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 71,850 | $0.00 Strike: $72.34 | $0.00 |
DisclosureSEC source: 0001127602-20-010515 · form4.xml · derivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,850 Underlying: Common Stock · 71,850 shares Expires 2030-03-10 F1 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 01:16 UTC |
Cogan John FrancisDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-010172 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,307 Underlying: Common Stock · 2,413 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 11, 2011. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 01:16 UTC |
Cogan John FrancisDirector
|
SaleCommon Stock | 2,413 | $77.97 | $188,141.61 |
DisclosureSEC source: 0001127602-20-010172 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 01:16 UTC |
Cogan John FrancisDirector
|
Exercise / conversionCommon Stock | 2,413 | $19.63 | $47,367.19 |
DisclosureSEC source: 0001127602-20-010172 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 00:40 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
SaleCommon Stock | 1,100 | $71.26 | $78,383.03 |
DisclosureSEC source: 0001127602-20-009244 · form4.xml · nonDerivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,644 F3 · kind: The sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F5 · price: Sale prices reported for the transactions reported here range from $71.22 to $71.33. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 00:40 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
SaleCommon Stock | 9,341 | $70.83 | $661,630.50 |
DisclosureSEC source: 0001127602-20-009244 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,744 F3 · kind: The sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F4 · price: Sale prices reported for the transactions reported here range from $70.21 to $71.21. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:44 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 42,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-009245 · form4.xml · derivative · entry 5 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,932 Underlying: Common Stock · 42,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 1/3 vest on each yearly anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 1/3 vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:44 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 11,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-009245 · form4.xml · derivative · entry 4 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,857 Underlying: Common Stock · 11,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:44 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 25,922 | $69.36 | $1,797,949.92 |
DisclosureSEC source: 0001127602-20-009245 · form4.xml · nonDerivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,570 Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:44 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 42,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-009245 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:44 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 11,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-009245 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 22:13 UTC |
Lofton Kevin EDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 21,720 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-007698 · form4.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,720 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 22:13 UTC |
Lofton Kevin EDirector
|
Exercise / conversionCommon Stock | 21,720 | $19.63 | $426,363.60 |
DisclosureSEC source: 0001127602-20-007698 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2020 Filed Mar 4, 2020 00:40 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
GrantCommon Stock | 395 | $53.67 | $21,199.26 |
DisclosureSEC source: 0001127602-20-009244 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,085 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2019 through February 15, 2020. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2020. Read SEC document |
| February 15, 2020 Filed Mar 13, 2020 00:10 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
GrantCommon Stock | 264 | $53.67 | $14,168.62 |
DisclosureSEC source: 0001127602-20-010508 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,858 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2019 through February 15, 2020. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2020. Read SEC document |
| February 15, 2020 Filed Mar 13, 2020 00:15 UTC |
Dickinson Andrew DEVP, Chief Financial Officer
|
GrantCommon Stock | 395 | $53.67 | $21,199.26 |
DisclosureSEC source: 0001127602-20-010511 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,987 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2019 through February 15, 2020. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.